Skip to main content
Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRSN ISIN · US59045L1061 LEI · 529900VWD5VDZ7PVOS22 US Manufacturing
Open in API
Filings indexed 700 across all filing types
Latest filing 2019-06-11 Director's Dealing
Country US United States of America
Listing US MRSN

About Mersana Therapeutics, Inc.

https://www.mersana.com/

Mersana Therapeutics, Inc. is a clinical-stage company focused on discovering and developing life-changing antibody-drug conjugates (ADCs) for patients fighting cancer. The company utilizes its proprietary and differentiated ADC platforms, which incorporate both cytotoxic and immunostimulatory payloads, to develop its pipeline. These platforms are designed to customize and optimize ADCs, aiming to overcome the limitations of first-generation technologies by improving efficacy and tolerability. Mersana is advancing a portfolio of ADC candidates to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2019-06-11 English
4
Director's Dealing
2019-06-11 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 7, 2019. The content focuses on the submission of matters to a vote of security holders at the company's Annual Meeting, including election of board members and ratification of the independent auditor. It provides detailed voting results for these proposals. There is no financial data or comprehensive report content, but rather the official results of shareholder votes. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is 4299 characters, which is short and consistent with a voting results announcement rather than a full report. Therefore, the correct classification is DVA with high confidence.
2019-06-07 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 1, 2019, by Mersana Therapeutics, Inc. It reports "Other Events" under Item 8.01, specifically the issuance of a press release providing interim Phase 1 data for a drug candidate. The document includes the press release as an exhibit but does not contain detailed financial statements or comprehensive financial analysis. The length is 3407 characters, which is relatively short and consistent with a current report announcing an event rather than a full financial report. Form 8-K filings are current reports used to announce major events that shareholders should know about, such as press releases on clinical trial data. This does not fit the definitions of Annual Report, Interim Report, Earnings Release, or other detailed financial filings. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other categories.
2019-06-05 English
10-Q
Interim / Quarterly Report Q1 2019
2019-05-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 9, 2019, by Mersana Therapeutics, Inc. It announces the issuance of a press release regarding financial results for the quarter ended March 31, 2019. The text explicitly states that the press release is furnished as an exhibit and that the information is being furnished, not filed, indicating this is an announcement of financial results rather than the full financial report itself. The document is relatively short (4116 characters) and primarily serves to announce the earnings release. Therefore, this document is best classified as an Earnings Release (ER).
2019-05-09 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.